OTC · CIK 0001859007
ZVSA ZyVersa Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 16, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at ZyVersa Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 8 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 11, 2025 | Karen A. Cashmere Chief Commercial Officer | AGrant or award Stock Optionsderivative | +48,100 | $0.00 | $0 | 48,100 | Jul 16, 2025 |
| Jul 11, 2025 | Robert G Finizio director | AGrant or award Stock Optionsderivative | +11,066 | $0.00 | $0 | 11,066 | Jul 15, 2025 |
| Jul 11, 2025 | Gregory Gene Freitag director | AGrant or award Stock Optionsderivative | +11,066 | $0.00 | $0 | 11,066 | Jul 15, 2025 |
| Jul 11, 2025 | Stephen C. Glover Chief Executive Officer | AGrant or award Stock Optionsderivative | +136,900 | $0.00 | $0 | 136,900 | Jul 15, 2025 |
| Jul 11, 2025 | Pablo A. Guzman Chief Medical Officer | AGrant or award Stock Optionsderivative | +48,900 | $0.00 | $0 | 48,900 | Jul 15, 2025 |
| Jul 11, 2025 | Min-Chul Park director | AGrant or award Stock Optionsderivative | +11,066 | $0.00 | $0 | 11,066 | Jul 15, 2025 |
| Jul 11, 2025 | James Sapirstein director | AGrant or award Stock Optionsderivative | +11,066 | $0.00 | $0 | 11,066 | Jul 15, 2025 |
| Jul 11, 2025 | Peter Wolfe Chief Financial Officer | AGrant or award Stock Optionsderivative | +60,100 | $0.00 | $0 | 60,100 | Jul 15, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Karen A. CashmereChief Commercial Officer
- Robert G Finiziodirector
- Gregory Gene Freitagdirector
- Stephen C. GloverChief Executive Officer
- Pablo A. GuzmanChief Medical Officer
- Min-Chul Parkdirector
- James Sapirsteindirector
- Peter WolfeChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.